注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Senti Biosciences Inc(原名:Dynamics Special Purpose Corp.)是一家临床前生物技术公司。该公司正在开发利用它的基因电路平台技术设计的细胞和基因疗法,以治愈疾病。该公司的先进的基因电路候选产品针对用于肿瘤学的同种异体CAR-NK细胞。该公司的临床前阶段候选产品包括SENTI-202、SENTI-301和SENTI-401。它正在开发它的SENTI-202候选产品作为逻辑门控(OR+NOT)同种异体CAR-NK细胞疗法,旨在靶向和消除急性髓性白血病(AML)细胞,同时保留健康的骨髓。该公司的SENTI-301候选产品是一种多臂同种异体CAR-NK细胞疗法,正在开发用于治疗肝细胞癌(HCC)。该公司的SENTI-401候选产品是一种逻辑门控同种异体CAR-NK细胞疗法,它正在开发以靶向和消除结肠直肠癌(CRC)细胞。基因电路平台是它的技术平台。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Martin Fussenegger | - | - | Member of Scientific Advisory Board |
Michael D. Varney | 65 | 2021 | Member of Scientific Advisory Board |
James J. Collins | 57 | 2021 | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director |
Robin G. Taylor | - | 2021 | Member of Scientific Advisory Board |
Michael Andreeff | - | - | Member of Scientific Advisory Board |
Lawrence Fong | - | - | Member of Scientific Advisory Board |
Edward T. Mathers | 63 | 2016 | Independent Director |
Michael Kalos | - | 2021 | Member of Scientific Advisory Board |
Timothy K. Lu | 42 | 2016 | Co-Founder, CEO, President & Director |
Omid C. Farokhzad | 54 | 2022 | Independent Director |
Ahmad Khalil | - | - | Member of Scientific Advisory Board |
Brenda G. Cooperstone | 58 | 2019 | Independent Director |
Susan D. Berland | 69 | 2021 | Senior Financial Executive & Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核